Access to affordable inhaled medicines for chronic respiratory diseases is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease stakeholder meeting found opportunities to improve access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder efforts.
